Effect of combined low dose Gemcitabine and Oxaliplatin in the treatment of advanced or metastatic urothelial carcinoma
10.3760/cma.j.issn.1000-6702.2014.03.006
- VernacularTitle:低剂量吉西他滨联合奥沙利铂方案在晚期尿路上皮癌化疗中的疗效和安全性分析
- Author:
Wenhui SONG
;
Hongshun MA
;
Shiqiang YANG
;
Qingtong MA
;
Guangming LIU
- Publication Type:Journal Article
- Keywords:
Gemcitabine;
Oxaliplatin;
Urothelial carcinoma;
Combined chemotherapy
- From:
Chinese Journal of Urology
2014;35(3):182-186
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effect and toxicities of low dose Gemcitabine combined with Oxaliplatin in the treatment of advanced or metastatic uroedthelial carcinoma.Methods A total of 42 patients pathologically confirmed advanced or metastatic urothelial carcinoma (23 bladder cancer cases,11 ureteral carcinoma cases,and 8 renal pelvic carcinoma cases) were reviewed.Karnofsky score for each patient before treatment was more than 60.Combined treatment with Gemcitabine and Oxaliplatin regimen was as follows:Gemcitabine 700 mg/m2,iv infusion at day 1,8 and day 15,Oxaliplatin 100 mg/m2,iv infusion at day 2.The regimen was administered for more than 2 cycles (every 4 weeks) and the response rate was evaluated.The regimen was used in palliative chemotherapy and adjuvant chemotherapy,respectively.Results According to WHO evaluation criteria on therapeutic effectiveness,7 patients (16.7％) had complete response,13 patients (30.9％) had partial response,14 cases (33.3％) remained stable status,and 8 cases (19.1％) had progression.The overall response rate was 47.6％.The main side effects included thrombocytopenia,leucopenia,nausea,vomiting and alopecia,which were mild to moderate and disappeared when the chemotherapy was ceased.No chemotherapy related death occurred.Conclusions Combined treatment with low dose Gemcitabine and Oxaliplatin is effective for advanced or metastatic urothelial carcinoma,with mild and tolerable toxicities.
